[{"data":1,"prerenderedAt":23},["ShallowReactive",2],{"notifications-general-de":3,"compound-CBT-de":4},"Wegen der Sommerferien arbeitet das Labor vom 22. Juli bis 9. August 2026 nach einem geänderten Zeitplan. Analyseergebnisse sind 7 bis 10 Tage nach Proben­eingang verfügbar. Vielen Dank für Ihr Verständnis.",{"name":5,"shortname":6,"synonyms":7,"cas":8,"molMass":9,"pubchemLink":10,"structure":11,"important":12,"synthetic":13,"compoundClass":14,"asociationImage":17,"summarySet":18,"compoundEffectSet":22},"Cannabicitran","CBT","CBTC, (6aα,9β,10aα)-6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-1,9-epoxy-6H-dibenzo[b,d]pyran","31508-71-1",314.5,"https:\u002F\u002Fpubchem.ncbi.nlm.nih.gov\u002Fcompound\u002FCannabicitran","science\u002Fstructures\u002FCBT.png",true,false,{"id":15,"description":16},"2","Cannabinoids","",[19],{"summaryText":20,"language":21},"\u003Cp>Cannabicitran (CBT) is naturally found in hemp, albeit in rare quantities. It has demonstrated the ability to reduce intraocular pressure in rabbit tests, suggesting it may have potential use in managing conditions like glaucoma.The reduction in intraocular pressure is believed to be due to Cannabicitran's agonist activity at the NAGly receptor (GPR18), a target for many structurally related cannabinoids. \u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",null,[],1785925849718]